

***MASSACHUSETTS GENERAL HOSPITAL  
DEPARTMENT OF ORTHOPAEDIC SURGERY***

***GRAND ROUNDS***

***Michelle Ghert, MD, FRCSC***

*Professor, Department of Surgery, Division of Orthopaedic Surgery  
McMaster University  
Hamilton, Ontario, Canada*

***“Randomized Controlled Trials  
in Orthopaedic Oncology”***



***Thursday, May 25, 2023  
6:30am - 7:30am EST***

***Massachusetts General Hospital  
O’Keeffe Auditorium  
(HYBRID, In-person & on Zoom)***



**Thursday, May 25, 2023**  
**Massachusetts General Hospital**  
**Department of Orthopaedic Surgery**

**GRAND ROUNDS**

***O’Keeffe Auditorium***  
***(HYBRID, In-person & on Zoom)***  
**6:30am -7:30am EST**

**Michelle Ghert, MD, FRCSC** studied Medicine at Vanderbilt University in the United States and completed her orthopaedic surgery residency at Duke University. She then studied at the University of Toronto for her fellowships in orthopaedic oncology and cancer research. She was appointed as Assistant Professor at McMaster University in 2005 and was promoted to Full Professor in 2017.

She has led the Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) international randomized controlled trial (RCT), which was the first multicenter RCT in orthopaedic oncology. The study randomized 604 patients undergoing lower extremity endoprosthetic reconstruction of oncologic reasons to one or five days of postoperative prophylactic intravenous antibiotics. Patients were enrolled across 48 clinical sites in 12 countries and 6 continents. The study found that there was no difference in surgical site infections between randomized groups, but there was a significantly higher rate of antibiotic related complications in the five-day group. The PARITY study has won multiple collaboration and national research awards.

Dr. Ghert serves in the Presidential Line of the Musculoskeletal Tumor Society and as the inaugural Chair of the Strategies in Clinical Research Section of the Orthopaedic Research Society.

6:30am ***Welcome***

Kevin A. Raskin, MD  
*Chief, Orthopaedic Oncology Service*  
*Department of Orthopaedic Surgery*  
*Massachusetts General Hospital*  
*Associate Professor of Orthopaedic Surgery*  
*Harvard Medical School*  
*Program Director*  
*Fellowship in Orthopaedic Oncology*

6:35am ***“Randomized Controlled Trials in Orthopaedic Oncology”***

Michelle Ghert, MD, FRCSC

7:30am ***Wrap-up / Adjourn***

Kevin A. Raskin, MD